SureTrader SureTrader
Home > Boards > US OTC > Medical - Healthcare >

Theralase Technologies Inc. (TLTFF)

Add TLTFF Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 12/10/2016 12:45:05 PM - Followers: 56 - Board type: Free - Posts Today: 0


Jan 22, 2014 7:20 AM | about stocks: TLTFF


Theralase Technologies Inc. (TSX-V: TLT, US-OTCBB: TLTFF). They design, develop, manufacture and market, patented, super-pulsed laser technology used in biostimulative and biodestructive clinical applications. The Theralase technology platform targets several health-care sectors: First, for non-invasive pain management and clinical therapy, used in neural muscular skeletal conditions, including arthritis and osteoarthritis; Second, wound care and healing (including non-healing fractures and bone fracture regeneration); And third, research and development into combining patented photodynamic compounds (PDCs) with patented, super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacteria and viruses.

The company is currently focused on the commercialization (production, marketing and distribution) of the TLC-2000 Superpulsed Laser Technology to healthcare practitioners, and commercialization of the patented TLC-3000 Photo Dynamic Compound Cancer Technology through pre-clinical research and clinical trials.

Key Investment Highlights:

  • Working on breakthrough bladder cancer destruction technology and has achieved tremendous success in pre-clinical trials
    Proven clinical technology (TLC-1000) and commercial therapeutic laser business and brand developed over last 17 years, currently generating ~2M of revenue annually
    Rollout of new TLC-2000 technology in 2014, along with a new recurring revenue business model
    Strategic agreements in place with world renowned institutions to help advance research and mitigate expenses
    Competitive technical advantages (Cellular pathways: iNOS, ATP, Na+ / K+)
    Future technology (patented biofeedback technology and patented PDC cancer destruction)
    IP protection (multiple issued patents)
    Large addressable US markets ($ billions)
    No debt
    Positive cash flow / double digit growth
    Lots of opportunity for short-term and long-term growth (revenue & profit)
    Experienced management team (20+ years)
    Clear vision and execution strategy


Theralase has patented anti-cancer drugs known as Photo Dynamic Compounds (PDCs) which localize the DNA of cancer cells and when irradiated, destroy the DNA resulting in apoptosis (natural cell death). While PDCs are used in Photodynamic Therapy (PDT) as a potential treatment regime for a number of conditions, Theralase has discovered that they hold particular promise as treatment to particular cancers. Theralase PDCs have proven successful in destroying breast, colon, brain and bladder cancer cells. Recent lab results have shown that Theralase was able to completely destroy subcutaneous bladder cancer tumors in mouse models. "The achievement of this important milestone signifies that Theralase's leading drug candidate is effective in the destruction of cancer in a live animal model and can prevent the cancer from recurring," commented Roger White of Theralase.

Key Market Statistics:

  • US bladder cancer treatment annual spending was $3.9 billion in 2012
    70,000 new cases, > 14,000 deaths in the US each year
    386,000 new cases are diagnosed worldwide annually
    Standard treatment unchanged with no new drugs approved since 1998
    5th most common cancer, 4th in men, 8th in women
    Most expensive cancer to treat with a recurrence rate up to 80%
    70% of new bladder cancer cases are early stage disease and 90% of bladder cancers are Transitional Cell Carcinoma (TCC)

Theralase PDC Characteristics:

  • Up to 100% cancer cell kill at very low concentrations (< 0.8μM)

(click to enlarge)

  • More effective at killing cancer cells than FDA approved drugs

(668,000x ALA, 198x PHOTOFRIN)

  • Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment

(click to enlarge)

We are VERY IMPRESSED, and VERY EXCITED about these results! In 2012, annual spending for bladder cancer treatment in the US was $3.9 billion, and the current standard of care has been unchanged with no new drugs approved since 1998. Bladder cancer is the most expensive cancer to treat, and has a recurrence rate up to 80%. All of the mice which showed an initial response have remained cancer free, healed without scarring, and have developed normally after only one Theralase PDC treatment. Needless to say, the early results from Theralase look extremely positive. Imagine being able to not only provide treatment for bladder cancer, but to actually cure it, and stop it from coming back! The company is also working on developing further PDCs that can be used to treat a wide variety of other cancers (breast, colon, brain and lung), as well as bacteria and viruses.

  • The general patent protects 1,000s of molecules - essentially a library of PDCs
    Virtually 0% toxicity at high concentrations (> 100μM) leading to ultra-high safety profile
    Activated by laser light providing excellent specificity and selectivity
    Able to treat solid core hypoxic tumors, such as: breast, prostate and lung
    Research outsourced to and performed at world renowned Princess Margaret Cancer Centre
    Patented under numerous US and International Patents:
    Issued USA Patents: 6,962,910, 7,612,057, 8,148,360, 8,445,475
    Pending USA Patent Applications: 61/801,674, 13/863,089, 13/36595

To help explain how the procedure works we sketched a diagram:

(click to enlarge)

  1. A catheter is inserted into the patient
    The PDC is injected and saturates within the patient's bladder, penetrating the cellular membrane (DNA localizing)
    Fiber optics cables are inserted up the catheter into the bladder
    Using laser technology, light is irradiated 360°
    The entire procedure takes about 2 - 3 hours

Theralase is currently completing the validation of the orthotopic rat model, a dose toxicity study, GMP drug manufacture, and FDA Investigational New Drug (IND) application. The next phase is to complete an FDA phase 1/2a human clinical study with FDA breakthrough status, and then to execute a strategic partnership agreement with big pharmaceutical (pharma) company (upfront payments, co-development funds, annual recurring revenue streams).

Industry comparables:

(click to enlarge)

(click to enlarge)

Deals with comparable big pharma companies have yielded anywhere from $466M to $1B plus royalties.


The thing is, by the time clinical trials have been completed (assuming they're successful), Theralase will be trading many multiples higher than today. Look how excited investors got when Theralase first released PDC breast cancer results during January 2010, the intraday high for TLT was $1.39/share:

Read More :

Themes: Biotechnology, Micro Capitalization, Growth Opportunity, Pharmaceuticals, Cancer, Laser Technology, Photo Dynamic Compounds (PDCs) Stocks: TLTFF
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
TLTFF News: Theralase Anti-Cancer Technology Picks Up Steam 01/06/2015 07:00:00 AM
TLTFF News: Theralase CEO to Be Interviewed Today on Clear Channel Business Talk Radio DFW 1190AM 03/12/2014 07:05:00 AM
TLTFF News: Theralase Achieves Commercialization Milestone For Its Bladder Cancer Therapy 03/14/2013 07:00:04 AM
#2279   Looks like end of January for preliminary data. 123414 12/10/16 12:45:05 PM
#2278   Let the trials begin :) itsallgood11 12/09/16 11:36:24 AM
#2277   Toronto, Ontario - December 9, 2016, Theralase Technologies itsallgood11 12/09/16 07:18:35 AM
#2276 This is going to get i 123414 12/09/16 06:13:36 AM
#2275 -3 12/06/16 08:17:07 PM
#2274   At the North West corner of Front and -3 12/06/16 06:44:40 AM
#2273   Princess Margaret Ranks #2 in Cancer Research In 123414 12/04/16 12:43:23 PM
#2272   Zacks TLTFF Valuation .50 cents 123414 12/02/16 11:45:02 AM
#2271   I like slides 7-8-9. BIGKAHUNA57 12/01/16 12:38:57 PM
#2270   Thor also dug this out . -3 12/01/16 10:45:19 AM
#2269   3Q Presentation. Nice review with great details. BIGKAHUNA57 12/01/16 10:28:26 AM
#2268   BCG- Does everyone realize that one of the abun 11/30/16 09:27:18 AM
#2267   Full speed ahead now into the Clinical trial The Rainmaker 11/30/16 08:50:53 AM
#2266   TLT Demonstrates 12 Month Stability of Lead Anti-Cancer Drug itsallgood11 11/30/16 08:47:42 AM
#2265   Mr. Dumoulin-White concluded that, “The Company looks forward The Rainmaker 11/29/16 08:18:43 PM
#2264   TLTFF fast trial results 30 days for first results. The Rainmaker 11/29/16 08:18:10 PM
#2263   Theralase has been very successful in executing on The Rainmaker 11/29/16 08:11:50 PM
#2262 IBjim 11/29/16 07:40:46 PM
#2261   Yeah... I see those .45 on the l2. 123414 11/29/16 12:09:23 PM
#2260   Looks like somebody knows something. 123414 11/29/16 12:01:24 PM
#2259   Last year they released earning on November 30th. The Rainmaker 11/29/16 10:53:20 AM
#2258   Good volume good action thus far this morning.... MasterSalix 11/29/16 10:06:15 AM
#2257   Anyone here in a lab or who might -3 11/28/16 05:05:58 PM
#2256   Got my proxie statement voted yes for everything The Rainmaker 11/26/16 06:26:59 PM
#2255   From the Lab to a Clinical at Princiess 123414 11/25/16 02:23:19 PM
#2254   Treatment time is 30 days I think. suerte88 11/25/16 02:08:04 PM
#2253   "We think that by the beginning of December 123414 11/25/16 01:57:53 PM
#2252   Looking forward to news they have enrolled the The Rainmaker 11/25/16 01:09:47 PM
#2251   I don't know. It seems unclear. But if 123414 11/25/16 12:52:43 PM
#2250   Does Dr Frost own shares here, read something The Rainmaker 11/25/16 12:45:19 PM
#2249   Just nabbed a few for black Friday! 123414 11/25/16 12:43:04 PM
#2248   I thought the interview was telling. BIGKAHUNA57 11/22/16 07:00:59 PM
#2247   Well... if these expired... not 123414 11/22/16 06:50:55 PM
#2246   Links for Korelin report The Rainmaker 11/21/16 09:47:37 PM
#2245   Dr. MIchael Jewett interview posted on Korelin Report now. CUIN2 11/21/16 09:45:11 PM
#2244   There should be korelin report due out soon itsallgood11 11/21/16 03:43:39 PM
#2243   Phase1 c/trial = SUB 1 million dollars /ph2 123414 11/21/16 05:56:01 AM
#2242   Theralase, possessing both CTA and ITA approval, plans 123414 11/18/16 02:35:08 PM
#2241 123414 11/18/16 05:54:55 AM
#2240   I agree. Speculation alone could drive it CUIN2 11/17/16 09:50:19 PM
#2239   Called company today. Rw is on business trip. itsallgood11 11/17/16 09:41:34 PM
#2238   What are we voting on at the AGM 123414 11/17/16 11:47:03 AM
#2237   I'm excited too. I'm prepin to get some 123414 11/17/16 05:37:23 AM
#2236   Im still studying up here, bought some .19's The Rainmaker 11/16/16 07:23:07 PM
#2235   Are u new to tltff. Whats your personal itsallgood11 11/16/16 07:21:31 PM
#2234   Companies do PP's all the time and their The Rainmaker 11/16/16 07:16:48 PM
#2233   What is your opinion on the latest pp itsallgood11 11/16/16 07:12:05 PM
#2232   Here's a good link right into the audio The Rainmaker 11/16/16 07:02:15 PM
#2231   We would hope to have 1 or 2 123414 11/16/16 07:36:57 AM
#2230   Thank you for the reading material. The Rainmaker 11/15/16 12:41:45 AM